PARP inhibition in BRCA-mutated breast and ovarian cancers

被引：44
|
作者：
Chan, Stephen L. [1 ]
Mok, Tony
机构：
[1] Chinese Univ Hong Kong, State Key Lab S China, Sir YK Pao Ctr Canc, Dept Clin Oncol,Hong Kong Canc Inst, Hong Kong, Hong Kong, Peoples R China
来源：
LANCET | 2010年 / 376卷 / 9737期
关键词：
POLY(ADP-RIBOSE) POLYMERASE; PHASE-III; TUMORS;
D O I：
10.1016/S0140-6736(10)61119-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：211 / 213
页数：3
相关论文
共 50 条
  • [1] SOX5 inhibition overcomes PARP inhibitor resistance in BRCA-mutated breast and ovarian cancer
    Mithun Ghosh
    Min Sil Kang
    Nar Bahadur Katuwal
    Sa Deok Hong
    Seong Min Park
    Seul-Gi Kim
    Seung Ryeol Lee
    Yong Wha Moon
    Cell Death & Disease, 16 (1)
  • [2] PARP inhibition — moving beyond BRCA-mutated disease
    David Killock
    Nature Reviews Clinical Oncology, 2017, 14 : 71 - 71
  • [3] Immune profiling of BRCA-mutated breast cancers
    Force, Jeremy Meyer
    Abbott, Sarah
    Broadwater, Gloria
    Stashko, Ilona
    Westbrook, Kelly E.
    Kimmick, Gretchen Genevieve
    Sammons, Sarah LeNoir
    Hyslop, Terry
    Brauer, Heather Ann
    Mashadi-Hossein, Afshin
    Plichta, Jennifer Kay
    Hwang, Eun-Sil Shelley
    Kauff, Noah D.
    Weinhold, Kent J.
    Nair, Smita
    Castellar, Edgardo
    Marcom, Paul Kelly
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
    Nicoletto, Maria Ornella
    Baldoni, Alessandra
    Cavallin, Francesco
    Grego, Andrea
    Falci, Cristina
    Nardin, Margherita
    Mammano, Enzo
    Lai, Eleonora
    Torri, Valter
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [5] GYNAECOLOGICAL CANCER PARP inhibition - moving beyond BRCA-mutated disease
    Killock, David
    NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (02) : 71 - 71
  • [6] Progress in BRCA-Mutated Ovarian Cancer
    Spriggs, David R.
    Longo, Dan L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26): : 2567 - 2568
  • [7] DNA repair markers are differentially expressed in BRCA-mutated breast cancers
    Green, A.
    Caracappa, D.
    Nolan, C.
    Macmillan, D.
    Ellis, I.
    Rakha, E.
    VIRCHOWS ARCHIV, 2014, 465 : S19 - S19
  • [8] Could sensitivity to DDP of BRCA-mutated ovarian cancers be a predictor of longer survival?
    Artioli, Grazia
    Nicoletto, M. Ornella
    D'Andrea, Emma
    Palma, Maurizia Dalla
    Nardelli, Gianni
    Mocellin, Simone
    Falci, Cristina
    Ambrosini, Antonio
    Monfardini, Silvio
    ANNALS OF ONCOLOGY, 2004, 15 : 133 - 133
  • [9] Poly ADP ribose polymerase (PARP) for the treatment of BRCA-mutated advanced ovarian cancer
    Yunokawa, Mayu
    ANNALS OF ONCOLOGY, 2019, 30 : 47 - 47
  • [10] Subtypes in BRCA-mutated breast cancer
    Sonderstrup, Ida Marie H.
    Jensen, Maj-Britt R.
    Ejlertsen, Bent
    Eriksen, Jens O.
    Gerdes, Anne-Marie
    Kruse, Torben A.
    Larsen, Martin J.
    Thomassen, Mads
    Laenkholm, Anne-Vibeke
    HUMAN PATHOLOGY, 2019, 84 : 192 - 201
12345